COVID-19. COVID19 ,virus identified
Conditions
Interventions
Intervention 1: Intervention group 1: Hydroxychloroquine tablets 200 mg every 12 hours for one month fram Rooz daroo company. Intervention 2: Intervention group 2: Clarithromycin 500 mg capsules ever
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients with definitive diagnosis of COVID19 were hospitalized and treated Patients with COVID19 who still have dyspena and cough two weeks after discharge from the hospital Patients with COVID19 who continue to have lung involvement on CT SCAN two weeks after discharge
Exclusion criteria
Exclusion criteria: Patients with comorbidities such as chronic heart or lung disease before COVID19 The need for long-term use of drugs that have an irreversible interaction with the drugs used in the plan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dyspnea. Timepoint: Beginning of the study (before the intervention), 14, 30 days after the start of the study. Method of measurement: Medical Research Council(MRC).;Cough. Timepoint: Beginning of the study (before the intervention), 14, 30 days after the start of the study. Method of measurement: visual analogue scale(vas). | — |
Secondary
| Measure | Time frame |
|---|---|
| Lung function. Timepoint: At the beginning of the study (before the intervention) and 30 days later at the end of the study. Method of measurement: six minute walk test(6MW). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSima Bahrami
Iran University of Medical Sciences
Outcome results
None listed